ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
Dow Jones
38,239.66
0.40%
US Dollar vs MXN
17.1601
0.00%
Brent Oil
88.165
0.00%
Bitcoin
63,257.74
-0.76%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Allogene Therapeutics Inc (ALLO)

  7. Allogene Therapeutics Inc (ALLO) Noticias

ALLO Allogene Therapeutics Inc

2.91
0.055 (1.93%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Allogene Therapeutics Inc ALLO NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.055 1.93% 2.91 18:31:20
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.87 2.75 2.93 2.89 2.855
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
26/4/202407:30GLOBEAllogene Therapeutics Awarded Grant from the California..
09/4/202407:30GLOBEAllogene Therapeutics Announces Q2 Investor Conference..
14/3/202415:05GLOBEAllogene Therapeutics Reports Fourth Quarter and Full Year..
12/3/202407:30GLOBEAllogene Therapeutics and Arbor Biotechnologies Announce..
05/3/202407:30GLOBEAllogene Therapeutics to Report Fourth Quarter and Full Year..
28/2/202407:30GLOBEAllogene Therapeutics Announces Participation in the 44th..
16/2/202407:30EDGAR2Form 8-K - Current report
16/2/202407:30GLOBEAllogene Therapeutics to Restate Previously Filed Financial..
31/1/202416:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202416:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/1/202415:11EDGAR2Form 144 - Report of proposed sale of securities
16/1/202415:05GLOBEAllogene Therapeutics Announces Participation in Upcoming..
05/1/202407:00EDGAR2Form 8-K - Current report
04/1/202415:15GLOBEAllogene Therapeutics and Foresight Diagnostics Announce..
04/1/202415:05GLOBEAllogene Therapeutics Announces 2024 Platform Vision to..
03/1/202415:05GLOBEAllogene Therapeutics to Host Conference Call Previewing its..
20/12/202315:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202314:46EDGAR2Form 8-K - Current report
18/12/202315:17EDGAR2Form 144 - Report of proposed sale of securities
09/12/202311:00GLOBEAllogene Therapeutics Presents Comprehensive Safety Data of..
01/12/202307:30GLOBEAllogene Therapeutics Announces Participation in December..
03/11/202311:00GLOBEAllogene Therapeutics Presents Preclinical Data on a Novel..
02/11/202315:41EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
02/11/202315:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202315:03EDGAR2Form 8-K - Current report
02/11/202315:02GLOBEAllogene Therapeutics Reports Third Quarter 2023 Financial..
02/11/202308:00GLOBEAllogene Therapeutics Announces Poster Presentations at the..
30/10/202307:30GLOBEAllogene Therapeutics Announces Participation in November..
26/10/202307:30GLOBEAllogene Therapeutics to Report Third Quarter 2023 Financial..
17/10/202315:34EDGAR2Form 8-K/A - Current report: [Amend]
16/10/202307:31EDGAR2Form 8-K - Current report
16/10/202307:30GLOBEAllogene Therapeutics Appoints Geoffrey Parker as Chief..
27/9/202308:09GLOBEAllogene Therapeutics Announces Three Poster Presentations..
05/9/202307:30GLOBEAllogene Therapeutics Announces Participation in September..
14/8/202318:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202318:28EDGAR2Form 3 - Initial statement of beneficial ownership of..
14/8/202307:30GLOBEAllogene Therapeutics Appoints Earl Douglas as General..
09/8/202315:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/8/202316:15EDGAR2Form 144 - Report of proposed sale of securities
02/8/202315:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/8/202315:04EDGAR2Form 8-K - Current report
02/8/202315:02GLOBEAllogene Therapeutics Reports Second Quarter 2023 Financial..
26/7/202307:30GLOBEAllogene Therapeutics to Report Second Quarter 2023..
11/7/202305:06VWEthereum Blockchain Game Pikamoon Raises $3.6m, Final ICO..
10/7/202309:44VWMassive Gaming Celebrates Global Launch of House of..
10/7/202304:52VWWOW EARN Wallet Offers One-Stop Shop Features, Now Available..
10/7/202304:02VWSwaap v2 Launches: Revolutionizing DeFi Market Making with..
08/7/202309:03VWBritanniacoin’s Official Pre-release: introducing a unique..
06/7/202310:59VWTether Launches USDt On Kava
06/7/202303:03VWOKX to Launch Signal Trading Platform, Empowering Traders..

Su Consulta Reciente

NASDAQ
ALLO
Allogene Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados